Immune response to SARS-CoV-2 mRNA vaccination in multiple sclerosis patients after rituximab treatment interruption

Peripheral B cell depletion via anti-CD20 treatment is a highly effective disease-modifying treatment for reducing new relapses in multiple sclerosis (MS) patients. A drawback of rituximab (RTX) and other anti-CD20 antibodies is a poor immune response to vaccination. While this can be mitigated by t...

Descripció completa

Dades bibliogràfiques

Autors principals:	Remigius Gröning, Andy Dernstedt, Clas Ahlm, Johan Normark, Peter Sundström, Mattias N. E. Forsell
Format:	Artigo
Idioma:	Inglês
Publicat:	Frontiers Media S.A. 2023-07-01
Col·lecció:	Frontiers in Immunology
Matèries:	multiple sclerosis vaccination COVID-19 rituximab B cell immunology
Accés en línia:	https://www.frontiersin.org/articles/10.3389/fimmu.2023.1219560/full
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!